Extended surgical resection for stage III thymic tumors

Giovanni Leuzzi, Ugo Pastorino

Thoracic Surgery Unit, IRCCS Istituto Nazionale dei Tumori Foundation, Milan, Italy

Abstract: Stage III thymic tumors (TTs) is a heterogeneous entity characterized by a variety of neoplasms with macroscopic invasion of different intrathoracic structures as well as a different prognosis according to specific WHO histologic subtypes. This high variability in clinicopathologic behavior has long represented a deterrent for most clinicians in evaluating the optimal therapeutic strategy in such tumors. In this article, we give an overview on the multimodality therapies and analyzed the role of extended surgical procedures in more advanced cases.

Keywords: Stage III; thymic tumors (TTs); surgery; extended resection

Introduction

Thymic tumors (TTs) are rare malignancies accounting for 0.2–1.5% of all tumors (1) and thymoma represents the most common histology (~90% of all resected neoplasms) (2). Masoka-Koga stage III TTs occurs in 20–29% of all surgically treated thymomas (2,3). It is a heterogeneous entity characterized by a variety of locally-advanced neoplasms with macroscopic invasion of different intrathoracic structures (pericardium, lung, great vessels, phrenic nerve, diaphragm, chest wall) (4) as well as a different prognosis according to specific WHO histologic subtypes (5). This high variability in clinicopathologic behavior has long represented a deterrent for most clinicians in evaluating the optimal therapeutic strategy in such tumors. In order to overcome this heterogeneity, the new TNM staging system has divided the subset of locally-advanced TTs in three different stages according to the invasion of pericardium (stage II), neighbor organs (stage IIIa) or “unresectable” ones (stage IIIb) (6). Nevertheless, treatment of locally-advanced disease is still challenging in terms of surgical resectability as well as multimodality therapies adopted to improve survival and to control recurrences (7).

Outcome

From the surgical point of view, stage III TTs are subjected to a different range of radical resections (2,3,8). These data are of particular interest if considering that overall survival decreases with higher stages (III–IV) as well as incomplete resection, and recurrence rate increases in case of greater tumor size, stages III–IV, and more aggressive histologic features (2,9).

In the literature, few studies only have analyzed the subset of stage III TTs. Specifically, the 5-year overall survival still remains acceptable after surgery, ranging from 82% in Italy (10), 82.8% in Europe (7), ~72% in USA (11) and ~86% in Japan (12) (78% in our Institution). In major surgical series, different prognostic factors have been analyzed in outcome analysis, being completeness of resection (7,10), age (7,11,12) and administration of adjuvant therapy (AT) (7,11) the most significant ones. Similarly to other surgical series analyzing all stages, completeness of resection has been reported as the best prognosticator (9,13), confirming the role of surgery as the mainstay of treatment in such disease. On the other hand, given the technical difficulties encountered by surgeons in locally-advanced TTs (for large tumor dimension or involvement of vital structures), extended surgical procedures have been adopted to improve survival and to control recurrences (7).
mediastinal organs), the reported rate of radical resection is still highly variable among different studies (from 50% to 81.6% of all resected tumors) (2,3,7,8,10). This issue is of particular interest if considering that incomplete resections or debulking procedures may lead to increased recurrence rates and poorer prognosis and could not improve survival compared to biopsy alone (14).

**Pattern of recurrence**

Although prognosis seems acceptable, the recurrence rate is not negligible in surgically-treated stage III TTs. Specifically, even after R0 resection, relapse occurs in 17.5% to 30% of locally-advanced tumors (7,15,16) being the pleura and the tumor bed the most common sites (3,7). The European Society of Thoracic Surgeons (ESTS) evidenced that larger tumors (greater than 5 cm) are more likely to be associated with local recurrence than with distant recurrence (7). Furthermore, a recurrence analysis performed on the Japanese Nationwide Database documented that patients with specific pattern of invasion (pericardium, phrenic nerve, and pleura) were more likely to have relapse in the pleural or pericardial cavity (12,15).

### Role of extended resections

In the setting of multidisciplinary treatment of TTs, the decision on whether performing extended resection to obtain R0 resection is widely debated, particularly in the setting of stage III TTs with invasion of “vital” organs. In the literature, the surgical series reporting “very extended” procedures (i.e., superior vena cava or diaphragmatic resections) are limited (Table 1). With exception of pericardium, the main resected organs in extended thymectomy are the great vessels, ranging from 8.9% to 24.1% (24.8% in our experience) of all procedures (7,10), and specifically the brachiocephalic veins, the superior vena cava (17-22) and, even rarely, the aorta and epiaortic vessels (23).

As reported in Table 1, the invasion of great vessels is associated with worse overall survival (ranging from 45% to 56% at 5 years) compared to those patients with invasion of lung, pericardium or phrenic nerve, even in case of R0 resection (10). The reason for poor outcome in this subset of patients is probably related to their higher risk of systemic recurrences, which are generally not suitable for a redo-resection (10,24). However, although the prognosis in stage III TTs with invasion of mediastinal organs seems unexceptional, the surgeon should avoid any debulking procedures and be able to perform extensive resections (and

---

**Table 1** Kind of major extended resections and relative outcomes in stage III thymic tumors

<table>
<thead>
<tr>
<th>Author</th>
<th>Recruitment period</th>
<th>No. of patients</th>
<th>Organ resected [No. of patients]</th>
<th>Survival</th>
</tr>
</thead>
<tbody>
<tr>
<td>Shintani et al. (17)</td>
<td>1986–2001</td>
<td>11</td>
<td>SVC</td>
<td>NS</td>
</tr>
<tr>
<td>Chen et al. (18)</td>
<td>2001–2003</td>
<td>11</td>
<td>SVC</td>
<td>14/15 alive with 35 months follow-up</td>
</tr>
<tr>
<td>Spaggiari et al. (19)</td>
<td>1998–2004</td>
<td>9</td>
<td>SVC</td>
<td>45% (5 years)</td>
</tr>
<tr>
<td>Lanuti et al. (20)</td>
<td>1997–2007</td>
<td>3</td>
<td>SVC</td>
<td>56% (5 years)</td>
</tr>
<tr>
<td>Leo et al. (21)</td>
<td>1998–2008</td>
<td>8</td>
<td>SVC</td>
<td>NS</td>
</tr>
<tr>
<td>Okereke et al. (22)</td>
<td>1991–2009</td>
<td>10</td>
<td>SVC</td>
<td>27/38 alive</td>
</tr>
<tr>
<td>Ried et al. (23)</td>
<td>2010–2014</td>
<td>4</td>
<td>SVC [2], aorta [2]</td>
<td>5/6 alive 20.5 months follow-up</td>
</tr>
<tr>
<td>Leuzzi et al. (ESTS) (7)</td>
<td>1990–2010</td>
<td>370</td>
<td>Lung [130], pericardium [97], diaphragm [3], phrenic nerve [29], great vessels [33], combined [3]</td>
<td>82.8% (5 years)</td>
</tr>
<tr>
<td>Marulli et al. (10)</td>
<td>1980–2009</td>
<td>249</td>
<td>Lung [130], pericardium [107], phrenic nerve [54], great vessels [60]</td>
<td>66% (lung), 77% (pericardium), 74% (phrenic nerve), 39% (vessels) (10 years)</td>
</tr>
<tr>
<td>Our experience</td>
<td>2003–2015</td>
<td>78</td>
<td>Lung [97], pericardium [125], diaphragm [23], phrenic nerve [58], great vessels [42], chest wall [12]</td>
<td>78% (5 years)</td>
</tr>
</tbody>
</table>

SVC, superior vena cava; ESTS, European Society of Thoracic Surgeons; NS, not specified.
reconstruction as well) even in case of challenging cases with invasion of “vital” structures (i.e., vena cava, phrenic nerve or lung). Thus, it is highly recommended to manage TTs in high-volume centers and to resect all the organs close to the tumor (i.e., pericardium), even when the clinical staging is lower than stage III.

**Induction therapy (IT)**

In the setting of challenging cases, given the well documented chemo and radio-responsiveness of TTs, a variety of multimodality therapies has been employed through the years in order to improve prognosis and control relapse. Concerning administration of IT, few studies or clinical trials have been reported in the literature up to now (25-27), and even less in the setting of stage III alone (7,28). Reportedly, complete resection rate after IT varies between 22% and 92% (29), while 5-year OS approaches 80% (7,28). Although these data may suggest that resectability and survival is acceptable after IT in patients with locally-advanced disease (29), deeper analyses performed by the ESTS and the Japanese Nationwide Database evidenced that IT did not seem to affect survival (7) or may be an adverse prognostic factor as well (12), respectively. This is because IT is administered mainly to patients with more advanced disease [worse WHO histologic type, higher rate of incomplete resection (7), larger radiologic tumor size, higher number of involved sites, and invasion of the phrenic nerve (12)]. Furthermore, randomized trials on IT are hard to perform because of the following reasons: (I) TTs are extremely rare; (II) there is no appropriate comparison group (i.e., patients with potentially unresectable thymoma undergoing upfront surgery) or way to perform a propensity-score match for patients undergoing IT (7). Thus, the prognostic impact of IT is still controversial, and probably underpowered. Its real estimation would need further efforts in the setting of large prospective database.

**AT**

Contrarily to IT, the administration of AT is less debated in common practice. In the literature, some authors advocated no survival advantage in those patients receiving postoperative therapy (13,30). On the other hand, further analyses on larger databases have documented more positive results, especially in the setting of locally-advanced tumors. While a study on the SEER database evidenced improved disease-free survival only (11), a propensity-score match analysis performed on the ESTS database revealed that administration of AT was beneficial in terms of overall and cancer-specific survival either in stage III thymoma either in patients with specific pathologic features (7). These data have been also confirmed in a recent meta-analysis (31) as well as an investigation on 4,056 resected TTs enrolled in the National Cancer Data Base (32). Further studies are needed to define the optimal postoperative therapeutic strategy in the setting of locally-advanced TTs.

**Conclusions**

The management of stage III TTs is still challenging and constantly evolving. In order to provide the best chance to survival, all cases should be managed by a multidisciplinary team in high volume centers. IT may help the surgeon to obtain radicality in difficult cases with invasion of “unresectable” structures. On the other hand, the surgeon should avoid any debulking procedures and resect all the organs close to the tumor (even if the clinical staging is lower than stage III) or be able to perform extensive combined resections and reconstruction in more advanced cases. Further efforts should be made to evaluate the optimal combination of multimodality therapies in locally-advanced TTs.

**Acknowledgements**

None.

**Footnote**

Conflicts of Interest: The authors have no conflicts of interest to declare.

**References**


doi: 10.21037/med.2018.04.04

Cite this article as: Leuzzi G, Pastorino U. Extended surgical resection for stage III thymic tumors. Mediastinum 2018;2:40.